Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
(DERM) $2.30 -MC $40 m -9 Marketed drugs and more product launches soon , cash balance $38 million and annual revenue to hit $70 million .. under radar stock with massive upside
Presentation
https://d1io3yog0oux5.cloudfront.net/_56df18fb639a06d224aa59b361fc1fb6/journeymedicalcorp/db/2208/19996/pdf/JMC+Company+Overview+-+0422.pdf
(DERM) $2.35 -MC $40 m -9 Marketed drugs and more product launches soon , cash balance $38 million and annual revenue to hit $70 million .. under radar stock with great upside
Presentation
https://d1io3yog0oux5.cloudfront.net/_56df18fb639a06d224aa59b361fc1fb6/journeymedicalcorp/db/2208/19996/pdf/JMC+Company+Overview+-+0422.pdf
(LIAN) $2 trading 40% under cash and has multiple blockbuster in late stage ..the company largest shareholder Perceptive Advisors bought a lot of shares even above 14 dollars per share ....this is a very attractive buyout target
Insider buying
http://openinsider.com/search?q=lian
https://www.lianbio.com/pipeline/
EYEN $2.20 NEW $12 tgt by Wainwirght
HC Wainwright Starts Eyenovia at Buy With $12 Price Target
10/05/2022 | 07:08am EDT
https://www.marketscreener.com/quote/stock/EYENOVIA-INC-40331595/news/HC-Wainwright-Starts-Eyenovia-at-Buy-With-12-Price-Target-41932504/
(ATHA) $3.05 trading 60% under cash ($6.70 per share) ,has great pipeline and very strong institutional investors ...this stock is a nice reboundplay
Pipeline
https://www.athira.com/pipeline/
Top Institutional Holders
https://www.cnbc.com/quotes/atha?tab=ownership
(DERM) $2.40 ..MC $41 m--9 Marketed Drug another Product to be launched in Q4 + Phase 3 readout in early next year ...Company has annual revenue of more than $70 million ..under radar company with big upside
Presentation
https://d1io3yog0oux5.cloudfront.net/_56df18fb639a06d224aa59b361fc1fb6/journeymedicalcorp/db/2208/19996/pdf/JMC+Company+Overview+-+0422.pdf
World War coming ,,things doesnt look good guys
Ukraine announces fast-track NATO membership bid, rules out Putin talks
https://www.reuters.com/world/europe/zelenskiy-says-ukraine-applying-nato-membership-2022-09-30/
EDSA up 21% ...next milestone is the ACD Phase 2b readout coming within 8 weeks ...
Edesa Biotech Reports Statistically Significant Mortality Reductions in Phase 2 ARDS Drug Study
https://www.streetinsider.com/Accesswire/Edesa+Biotech+Reports+Statistically+Significant+Mortality+Reductions+in+Phase+2+ARDS+Drug+Study/20647965.html
(CYTH) MC $16 m..2x BIG Drugs in Phase 3 & 2 ...cheapest Alzheimer stock on the market it could be the next SAVA
Summary
https://s3.amazonaws.com/b2icontent.irpass.cc/2573/187165.pdf
(CYTH) MC 16 m --CHEAPEST Alzheimer gem about to breakout
Pipeline Summary
https://s3.amazonaws.com/b2icontent.irpass.cc/2573/187165.pdf
(NLSP) $0.92 ..BIG results coming THIS week ...market cap only $19 million so positive readout could push this low floater toward $3
NLS Pharmaceutics To Host Virtual Key Opinion Leader Event on September 30, 2022 After Release of Quilience(R) Top-Line Phase 2a Narcolepsy Results
https://finance.yahoo.com/news/nls-pharmaceutics-host-virtual-key-120000320.html
(AYTU) $0.18 next hot RS stock which trading under cash balance ...RS expected early next month
(CYTH) MC $15 m .CHEAPEST Alzheimer stock in the entire sector ...company has an orphan drug in phase 3 trial ongoing and Alzheimer treatment in Phase 2 trial .this stock could be the biggest opp in the Alzheimer area .
Fact Sheet
https://s3.amazonaws.com/b2icontent.irpass.cc/2573/187165.pdf
Cyclo Therapeutics: Addressing The Fundamentals Of Alzheimer's Disease
https://seekingalpha.com/article/4469809-cyclo-therapeutics-addressing-fundamentals-of-alzheimers-disease
from the SA article "At this point time, Cyclo Therapeutics has a high upside and investment in the company presents relatively few risks. In my opinion (which is based on nearly twenty years of studying Alzheimer’s disease), Cyclo Therapeutics is developing one of the few drugs that attacks Alzheimer’s disease at its core."
Russia will destroy the US terrorists and their Nato vasals so the earth will be a better place
(ABEO) $4 ..BIG Phase 3 results within next 14 days...market cap only 24 million this low floater could double on positive results
"Topline data from the Phase 3 VIITAL™ study of EB-101 in RDEB is on track for late third quarter to early fourth quarter of 2022 "
Alliance Global Partners initiates Abeona Therapeutics Inc. (ABEO) with buy rating and Price Target $20
Alliance Global Partners analyst James Molloy initiated coverage of Abeona Therapeutics with a Buy rating and $20 price target. EB-101 for for the treatment of recessive dystrophic epidermolysis bullosa "has a clear, near-term path to possible approval," Molloy tells investors in a research note. The analyst says the Phase 1/2a data looked good and that he expects it could be replicated in the Phase 3. It targets a small patient population, but should command an orphan drug price point, contends Molloy.
ABEO $4 buy rating $20 tgt ...Phase 3 data should come within next 14 days
Alliance Global Partners initiates Abeona Therapeutics Inc. with buy rating and Price Target $20
Alliance Global Partners analyst James Molloy initiated coverage of Abeona Therapeutics with a Buy rating and $20 price target. EB-101 for for the treatment of recessive dystrophic epidermolysis bullosa "has a clear, near-term path to possible approval," Molloy tells investors in a research note. The analyst says the Phase 1/2a data looked good and that he expects it could be replicated in the Phase 3. It targets a small patient population, but should command an orphan drug price point, contends Molloy.
(ABEO) $3.90 --BIG P3 results could hit the wire any day now ,,market cap of 23 million is very low so this low floater could jump toward 10 dollar on positive data
"Topline data from the Phase 3 VIITAL™ study of EB-101 in RDEB is on track for late third quarter to early fourth quarter of 2022 "
AYTU 0.21 ..R/S in October ...stock trading under cash and has marketed drug + big phase 3 asset ...this is a hotter pick than ADTX and NRBO
Presentation
https://irdirect.net/template_files/1081/images/Aytu_BioPharma_Corporate_Presentation_August_2022.pdf
TENX 0.24 "News" buyout or merger soon
https://finance.yahoo.com/news/tenax-therapeutics-announces-evaluation-strategic-123000231.html
Tenax Therapeutics and its Board of Directors believe the current valuation of the Company does not accurately reflect the potential value of its clinical-stage pipeline.
The Company will therefore explore a diverse range of strategic options to help drive shareholder value including, among other things, a sale, merger, or other strategic transaction.
BEAT runninggg
Tenx 0.23 Halted ...
bought AYTU 0.22 --RS likely next month ...company has already many approved drugs and low valuation of 13 million trading under cash balance of $28 million
https://ih.advfn.com/stock-market/NASDAQ/aytu-biopharma-AYTU/stock-news/88839610/proxy-statement-notice-of-shareholders-meeting-p
A special meeting of Stockholders of Aytu BioPharma, Inc. will be held virtually on October 5, 2022, at 10:00 a.m., Mountain Time at
1. To approve an amendment to our Certificate of Incorporation to effect a reverse stock split at a ratio of any whole number up to 1-for-20, as determined in the discretion of our board of directors (the “Board” or the “Board of Directors”), at any time before October 4, 2023 (the “Reverse Stock Split Proposal”); and
2. Approve the adjournment of the special meeting, if necessary, to continue to solicit votes for the Reverse Stock Split Proposal (the “Adjournment Proposal”).
back in TENX at 0.22 ...
TENX 0.28 rallyyyyyyyyyyyyy
TENX 0.24 next RS bombb
TENX about to explodeeeee ..its one of the most attractive RS gems because of their 2x Phase 3 ready assets and super low valuation of 5 million
(TENX) 0.21 has 2x Phase 3 ready Products ...market cap only 5 million this one likely to rally very hard once RS is done
pipeline below
https://tenaxthera.com/products/
TENX 0.22 -RS gem
(TENX) 0.21 has 2x Phase 3 ready Products ...market cap only 5 million.. this one could be the next NRBO
pipeline below
https://tenaxthera.com/products/
TENX 0.20 still a great opp to load up ahead of R/S , this gem is way better than ADTX which is up over 100%
TENX 0.20 next R/S gem like NRBO
has 2x Phase 3 ready Products ..market cap only 5 million dollar
https://tenaxthera.com/products/
(TENX) 0.21 has 2x Phase 3 ready Products ...market cap only 5 million this one likely to rally very hard once RS is done
pipeline below
https://tenaxthera.com/products/
TENX 0.22 ..MC $5 m next RS gem
(DERM) $3.10 ..MC $52m has 9x Marketed Drugs and more to come ...Cash balance $38 million ...heavily underpriced biotech which is still under radar
Company presentation
https://d1io3yog0oux5.cloudfront.net/_56df18fb639a06d224aa59b361fc1fb6/journeymedicalcorp/db/2208/19996/pdf/JMC+Company+Overview+-+0422.pdf
(BEAT) $1.28 ..MC $10 mil - FDA approval expected within 2 months ...great upside on this low floater ...
"HeartBeam Announces FDA Submission of HeartBeam AIMI™ Product
Submission Seeks Approval for the Company’s Proprietary ECG Technology to Aid in Diagnosis of Heart Attack in $500 million Total Addressable Market"
(ABEO) $3.80 --BIG Phase 3 imminent ...Market cap only 23 million
"Topline data from the Phase 3 VIITAL™ study of EB-101 in RDEB is on track for late third quarter to early fourth quarter of 2022 "